Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial–mesenchymal transition in cancer cells
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The epithelial–mesenchymal transition (EMT) is a highly networked cellular process which involves cell transition from the immotile epithelial to the motile mesenchymal phenotype, whereby cells lose their cell–cell adhesion and cell polarity. This important process is one of the underlying mechanisms for enabling invasion and metastasis of cancer cells which is considered as malignant phase of tumor progression. However, the molecular mechanisms of this process are not fully clarified. It is reported that Sirtuin1 (SIRT1), a NAD+ dependent class III histone deacetylase is associated with tumor metastasis through positive regulation of EMT in several types of cancers. Recent studies confirmed that up and down regulation of SIRT1 expression remarkably change the migration ability of different cancer cells in vitro and tumor metastasis in vivo. Also, according to this fact that carcinomas as the main human solid tumors, originate from different epithelial cell types, SIRT1 role in EMT has received a great attention due to its potential role in tumor development and metastasis. Therefore, SIRT1 has been proposed as a key regulator of cancer metastasis by promoting EMT, although little is known about the cleared effect of SIRT1 in this transition. Our aim in this review is to explain in more detail the role of SIRT1 in various signaling pathways related to carcinogenesis, with the focus on the promoting role of SIRT1 in EMT as a potential therapeutic target to control EMT and to prevent cancer progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487 · cited 2×
“These TFs cooperate in activation and repression of target genes and also in the expression of each other (De Craene & Berx, 2013; Peinado et al., 2007).”
BackgroundThe role for autophagy in cancer
White, E. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73941 · Cited by 1,332
Mechanism of Human SIRT1 Activation by Resveratrol
Borra, M. T., Smith, B. C., & Denu, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501250200 · Cited by 1,065
Physiology and function of the tight junction
Anderson, J. M., & Van Itallie, C. M. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002584 · Cited by 1,059
SIRT1 Functionally Interacts with the Metabolic Regulator and Transcriptional Coactivator PGC-1α
Nemoto, S., Fergusson, M. M., & Finkel, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501485200 · Cited by 1,047
Mattagajasingh, I., Kim, C.-S., Naqvi, A., Yamamori, T., Hoffman, T. A., Jung, S.-B., DeRicco, J., Kasuno, K., & Irani, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704329104 · Cited by 881
SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging
Oberdoerffer, P., Michan, S., McVay, M., Mostoslavsky, R., Vann, J., Park, S.-K., Hartlerode, A., Stegmuller, J., Hafner, A., Loerch, P., et al. (2008) · Cell · doi:10.1016/j.cell.2008.10.025 · Cited by 852
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF‐κB
Chen, L., Mu, Y., & Greene, W. C. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf660 · Cited by 827
Calorie restriction–the SIR2 connection
Guarente, L., & Picard, F. (2005) · Cell · doi:10.1016/j.cell.2005.01.029 · Cited by 793 · cited 2×
“…neuro- degeneration, age-related disorders, obesity, heart disease, inflammation, cancer, and immunity (Clark-Knowles et al., 2017; Dong et al., 2014; Guarente & Picard, 2005; Lin et al., 2012; Sansone et al., 2013; Qiang et al., 2012; Vinciguerra et al., 2012; Wang, Sengupta, et al., 2008; Wu…”
BackgroundSIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine
Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Kim, R., Ge, E., Mostoslavsky, R., et al. (2013) · Nature · doi:10.1038/nature12038 · Cited by 697 · cited 1×
“…suppresses PTEN, Rb, p53, p73, HIC1which are key tumor suppressors, thus it can promote tumor development (Chen et al., 2005; Dai, Wang, Sun, Lin, & Wang, 2007; Guarente, 2014; Ikenoue, Inoki, Zhao, &Guan, 2008; Jiang et al., 2013; Luo et al., 2001; Vaziri et al., 2001; Wong & Weber, 2007).”
SIRT1 Controls Endothelial Angiogenic Functions During Vascular Growth
Potente, M., Ghaeni, L., Baldessari, D., Mostoslavsky, R., Rossig, L., Dequiedt, F., Haendeler, J., Mione, M., Dejana, E., Alt, F. W., et al. (2007) · Genes & Development · doi:10.1101/gad.435107 · Cited by 608 · cited 2×
“by deacetylation of FOXO1, HIF1, and Delta-like ligand 4 (DLL4) promotes tumor angiogenesis (Potente et al., 2007; Xie, Liu, & He, 2012).”
BackgroundResveratrol is not a direct activator of SIRT1 enzyme activity
Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S., Atangan, L., & Wang, M. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00901.x · Cited by 426 · cited 2×
“However, there is evidences suggesting that resveratrol is not a direct activator of SIRT1 (Beher et al., 2009; Guarente, 2007).”
Backgroundp53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3
Wales, M. M., Biel, M. A., Deiry, W. E., Nelkin, B. D., Issa, J.-P., Cavenee, W. K., Kuerbitz, S. J., & Baylin, S. B. (1995) · Nature Medicine · doi:10.1038/nm0695-570 · Cited by 421 · cited 2×
“On the other hand, hypermethylated in cancer 1 (HIC1) as a tumor suppressor forms a complex with SIRT1 which repress SIRT1 transcription via direct binding to its promoter (Wales et al., 1995), thus lack of HIC1 expression results in an elevated SIRT1 level.”
BackgroundLin, Z., Yang, H., Kong, Q., Li, J., Lee, S.-M., Gao, B., Dong, H., Wei, J., Song, J., Zhang, D. D., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.03.024 · Cited by 315
Activation of Stress Response Gene SIRT1 by BCR-ABL Promotes Leukemogenesis
Yuan, H., Wang, Z., Li, L., Zhang, H., Modi, H., Horne, D., Bhatia, R., & Chen, W. (2012) · Blood · doi:10.1182/blood-2011-06-361691 · Cited by 182
Epithelial cell–cell junctions and plasma membrane domains
Giepmans, B. N. G., & van IJzendoorn, S. C. D. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.07.015 · Cited by 170
Alcaín, F. J., & Villalba, J. M. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902762893 · Cited by 137 · cited 1×
“SIRT1 overexpression leads to Lys382 deacetylation at C-terminal of p53 which diminishes its transcriptional activity on downstream key genes such as mir-34a (Alcain & Villalba, 2009a, 2009b; Luo et al., 2001; Yi & Luo, 2010).”
BackgroundRevelations into resveratrol's mechanism
(2012) · Nature Medicine · doi:10.1038/nm.2727 · Cited by 17 · cited 4×
“It has been shown that resveratrol is a direct activator of SIRT1 in vitro (Borra, Smith, & Denu, 2005; Guarente, 2007), which also activates SIRT1 gene expression (Schirmer et al., 2012).”
BackgroundInfluential
Cited by
(2024) · doi:10.7554/elife.87873.3 · Cited by 6
Islam, A., Chang, Y.-C., Chen, X.-C., Weng, C.-W., Chen, C.-Y., Wang, C.-W., Chen, M.-K., Tikhomirov, A. S., Shchekotikhin, A. E., & Chueh, P. J. (2023) · doi:10.1101/2023.03.29.534690
Islam, A., Chang, Y.-C., Chen, X.-C., Weng, C.-W., Chen, C.-Y., Wang, C.-W., Chen, M.-K., Tikhomirov, A. S., Shchekotikhin, A. E., & Chueh, P. J. (2024) · doi:10.7554/elife.87873.2
Metadata
- Authors
- Choupani, J., Mansoori Derakhshan, S., Bayat, S., Alivand, M. R., & Shekari Khaniani, M.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2018-01-15
- Volume
- 233
- Issue
- 6
- Pages
- 4443-4457
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2772086055
- Cited by
- 51
- References
- 18
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.